GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF

Exclusion Criteria

• •Acute Myocardial Infarction, unstable angina or revascularization procedure within 1 month;
• •planned cardiac surgery, expected to be performed within 3 months;
• •congenital or primary valvular etiology;
• •known hypersensitivity to study treatments;
• •significant liver disease;
• •pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception;
• •any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol;
• •presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy;
• •treatment with any investigational agent within 1 month before randomization;
• •patients already on treatment with n-3 PUFA or statin for whom the prescription is confirmed.
• •current serum creatinine level \>2.5 mg/dL;
• •current ALT, AST level \>1.5 times the upper normal limit;
• •current CPK upper normal limits.